Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer

Locally advanced gastric cancer with extensive lymph node metastasis is usually considered unresectable and so treated by chemotherapy. This trial explored the safety and efficacy of preoperative chemotherapy followed by extended surgery in the management of locally advanced gastric adenocarcinoma.

[1]  Soma Das,et al.  Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[3]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.

[4]  B. Goh,et al.  Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan‐induced neutropenia in Asian cancer patients , 2007, Cancer science.

[5]  I. Hyodo,et al.  Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[7]  S. Takao,et al.  Paraaortic lymphadenectomy in patients with advanced carcinoma of the upper-third of the stomach. , 2000, Hepato-gastroenterology.

[8]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[9]  A. Ohtsu,et al.  Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer , 2003, British Journal of Cancer.

[10]  M. Sasako.  Principles of surgical treatment for curable gastric cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  胃癌研究会.  Japanese classification of gastric carcinoma , 1995 .

[12]  A. Ohtsu,et al.  Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Nomura,et al.  Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. , 1999, Hepato-gastroenterology.

[14]  M. Kitamura,et al.  [Clinico-pathological studies and problems on para-aortic lymph node dissection--D4 dissection]. , 1996, Nihon Geka Gakkai zasshi.

[15]  A. Nashimoto,et al.  Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[17]  I sabel Mortara,et al.  International Union against Cancer , 1938, Nature.

[18]  A. Nashimoto,et al.  Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. , 2006, The Lancet. Oncology.

[19]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[20]  C. Roginski,et al.  Incidence and prognosis of N4 node involvement in gastric cancer , 1984, The British journal of surgery.

[21]  S. Law,et al.  Two approaches to cancer of the cardia. , 2006, The Lancet. Oncology.

[22]  S. Takahashi.  [Study of para-aortic lymph node metastasis of gastric cancer subjected to superextensive lymph node dissection]. , 1990, Nihon Geka Gakkai zasshi.

[23]  Japanese Gastric Cancer Association.  Japanese Classification of Gastric Carcinoma – 2nd English Edition – , 1998, Gastric Cancer.

[24]  R. Longo,et al.  Systemic treatment of gastric cancer. , 2009, Critical reviews in oncology/hematology.

[25]  A. Ohtsu,et al.  Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912) , 2007 .